Please use a PC Browser to access Register-Tadawul
Get It
Immatics Achieves Clinical Proof-Of-Concept For TCER Pipeline: IMA402 (PRAME) 30% cORR, IMA401 (MAGEA4/8) Up To 29% cORR; Initiates Phase 1b And Plans Combo In sqNSCLC
Immatics N.V. IMTX | 9.81 9.81 | +6.17% 0.00% Post |
